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Abstract
Insulin resistance (IR), an impaired cellular, tissue and whole body response to insulin, is a major pathophysiological defect
of type 2 diabetes mellitus. Although IR is closely associated with obesity, the identity of the molecular defect(s) underlying
obesity-induced IR in skeletal muscle remains controversial; reduced post-receptor signalling of the insulin receptor
substrate 1 (IRS1) adaptor protein and downstream effectors such as protein kinase B (PKB) have previously been
implicated. We examined expression and/or activation of a number of components of the insulin-signalling cascade in
skeletal muscle of 22 healthy young men (with body mass index (BMI) range, 20–37 kg/m2). Whole body insulin sensitivity
(M value) and body composition was determined by the hyperinsulinaemic (40 mU. min21.m22.), euglycaemic clamp and by
dual energy X-ray absorptiometry (DEXA) respectively. Skeletal muscle (vastus lateralis) biopsies were taken before and after
one hour of hyperinsulinaemia and the muscle insulin signalling proteins examined by western blot and
immunoprecipitation assay. There was a strong inverse relationship between M-value and BMI. The most striking
abnormality was significantly reduced insulin-induced activation of p42/44 MAP kinase, measured by specific assay, in the
volunteers with poor insulin sensitivity. However, there was no relationship between individuals’ BMI or M-value and protein
expression/phosphorylation of IRS1, PKB, or p42/44 MAP kinase protein, under basal or hyperinsulinaemic conditions. In the
few individuals with poor insulin sensitivity but preserved p42/44 MAP kinase activation, other signalling defects were
evident. These findings implicate defective p42/44 MAP kinase signalling as a potential contributor to obesity-related IR in a
non-diabetic population, although clearly multiple signalling defects underlie obesity associated IR.
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Introduction
Insulin resistance (IR) is a common pathophysiological state in
which higher than normal concentrations of insulin are required to
exert its biological effects in target tissues such as skeletal muscle,
adipose tissue and liver [1]. It is frequently associated with a
number of diseases including obesity, type 2 diabetes mellitus
(T2DM), polycystic ovary syndrome (PCOS) [2] and non-alcoholic
fatty liver disease (NAFLD) [3]. Skeletal muscle IR contributes
significantly to the metabolic derangements seen in these patients
considering that skeletal muscle accounts for the majority of
insulin-mediated glucose disposal in the post-prandial state [4].
The molecular basis of skeletal muscle IR is assumed to be due
to post-receptor defects in the insulin signal transduction pathway,
culminating in impaired translocation of the glucose transporter
GLUT4 to the cell membrane [5,6]. Most evidence implicates
functional defects such as impaired phosphorylation or activation,
rather than aberrant protein expression but these observations
mainly derive from studies in animals or analysis of relatively few
human biopsies. Insulin signalling is complex although the
majority of its control over glucose homeostasis requires two
pathways downstream of the insulin receptor substrates (IRSs):
namely the PI-3K/PKB pathway and the p42/p44 MAPK (ERK
1/2) pathway. There is evidence for increased phosphorylation of
a number of serine/threonine (Ser/Thr) sites on IRS1 in human
muscle with a subsequent impairment of tyrosine phosphorylation
of IRS1, thereby reducing downstream activation of PI-3 kinase
and PKB and hence decreasing activation of glucose transport and
other downstream events [5,7–9]. Similarly in obesity, in intact
muscle strips, there is impaired IRS-1 tyrosine phosphorylation
and PI-3 kinase activity in response to insulin stimulation [10].
We have previously demonstrated, in human skeletal muscle
from healthy controls, that IRS1 protein expression levels are
actually increased 3-fold following 1 h of hyperinsulinaemia.
Hence impairment of this induction of IRS1 would reduce
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downstream insulin signalling capacity, thereby contributing to the
development of IR prior to the appearance of T2DM [11].
Indeed, in mice, mutation of the serine 307 residue (Ser307) to
alanine (Ala) in IRS1, rendering IRS1 incapable of being
phosphorylated, reduced the insulin sensitivity of these animals,
suggesting a key role for Ser307 of IRS1 in regulating insulin
sensitivity [12]. Meanwhile, a recent global analysis of IRS1
phosphorylation indicated that multiple residues on IRS1 exhibit
altered phosphorylation in T2DM muscle but that these are not
abnormal in muscle from a pre-diabetic obese group [13]. This
questions the role of IRS1 phosphorylation in the initial
development of IR in this population. Interestingly induction of
Ser/Thr phosphorylation of IRS1 by insulin was similar in both
the control and T2DM volunteers, suggesting that obesity-induced
IR did not affect this aspect of insulin action. We have previously
reported that dysregulation of p42/p44 MAPK, rather than other
signalling proteins, may underlie reduced skeletal muscle glucose
transport and development of IR in ageing and in PCOS [2,14].
Therefore, it remains unclear whether all cases of IR with obesity
have defective PI3K-PKB signalling in the muscle and whether
additional signalling defects contribute to progression to T2DM.
The main aims of the current study were to establish whether
defective insulin signalling could be detected in human skeletal
muscle correlating with insulin resistance prior to the development
of diabetes, and determine whether this consisted of a single
common defect, or a range of signalling defects.
Materials and Methods
Ethics Statement
The subjects were informed of the experimental protocol both
verbally and in writing before giving their informed consent. The
experimental protocol was approved by the Tayside Ethics
Committee and was carried out according to the Helsinki
Declaration.
Participant characteristics
Twenty two healthy men, 2968y (SEM) participated in the
study. None were taking regular medication. Height (metres) and
weight (kilograms) were measured to determine the body mass
index (BMI). The cohort was recruited to include four groups of
individuals: seven of normal weight (BMI, 20–24 kg/m2), five
overweight (BMI 25–29) and ten obese (BMI$30 kg/m2). The
subjects were not habitually active. They were instructed to adhere
to their usual diet and to refrain from any strenuous physical
activity for 2 days before the study.
Study protocol
All subjects had a screening visit to assess family history of
diabetes and to confirm normal glucose tolerance with a standard
(75 g of powdered glucose) 2-hour oral glucose tolerance test.
Those individuals with a first-degree relative known to have
diabetes or with diabetes according to the World Health
Organisation diagnostic criteria (fasting glucose $7.0 mmol/l or
2 h glucose $11.1 mmol/l) were excluded from the study. Body
composition (fat mass, fat free mass and bone mineral content) was
determined by dual energy photon X-ray absorptiometry (DEXA;
HOLOGIC Discovery W, Bedford, MA, version 12.1).
Eligible subjects attended the Clinical Investigation Unit,
Ninewells Hospital at 08:00 having not eaten for 12 hours, for a
study protocol involving skeletal muscle biopsies and a hyperin-
sulinaemic, euglycaemic clamp [15]. A cannula was introduced
into a forearm vein for infusion of insulin (Actrapid, NovoNordisk
Copenhagen, Denmark) and 20% dextrose while on the contra-
lateral side a wrist or hand vein was cannulated retrogradely for
blood sampling. This arm was heated in a hot box at 65uC
throughout.
Quadriceps (vastus lateralis) muscle biopsies were taken, using
1% lignocaine anesthetic and the conchotome technique [16] at
the start of the hyperinsulinaemic, euglycaemic clamp. All biopsies
were taken using separate incisions and made from distal to
proximal areas of the quadriceps. The biopsy was snap-frozen in
liquid nitrogen and stored at 280uC until further analysis. Insulin
was infused at 40 mU. min21.m22 body surface area followed by a
variable infusion of 20% glucose to maintain plasma glucose
concentration at 5.2 mmol/l. A second muscle biopsy was taken
through a separate incision after one hour of the clamp. The
clamp was maintained for a further hour to assess insulin
sensitivity (M-value, see below).
Analytical Methods
Plasma. Plasma was separated from whole blood by centri-
fugation (300 g) immediately after collection. Plasma glucose was
measured with a YSI Stat2300 (Yellow Spring Instruments, Yellow
Spring, OH) immediately after collection of each sample; the
remainder of the plasma sample was frozen until further analysis.
Plasma insulin was measured by the Clinical Biochemistry
Department at Ninewells Hospital, Dundee, using a Siemens
Immulite 2000 Immunoassay system.
Preparation of Protein Extracts for Western Blotting or
Immunoprecipitation. Protein extracts were obtained as
detailed previously[11]. In brief, muscle biopsies were thawed in
ice and homogenized (Dounce, 10–15 strokes) in 0.5 ml ice-cold
lysis buffer (25 mM Tris-HCl (pH 7.4), 50 mM NaF, 100 mM
NaCl, 1 mM sodium vanadate, 5 mM EGTA, 1 mM EDTA, 1%
(v/v) Triton X-100, 10 mM sodium pyrophosphate, 0.27 M
sucrose, Complete Protease inhibitor cocktail tablets (1 tablet/
10 ml), and 0.1% (v/v) 2-mercaptoethanol). Protein lysates were
obtained from the supernatant fraction after 10 min centrifugation
at 13,000 r.p.m., and then pre-cleared for 1 h at 4uC with Protein
G-Sepharose in PBS 50% (v/v). This process removed contam-
inating antibodies present in the samples due to excess blood in the
muscle samples. We found this step to be vital for consistent results
with the subsequent immunoblot and immunoprecipitation steps.
Western Blot Analysis. Protein extracts (30–40 mg protein)
were separated on Novex SDS 4–12% polyacrylamide gels.
Following transfer to nitrocellulose membranes, blots were first
blocked with 5% (w/v) non-fat milk in TBST (Tris-buffered saline
containing 0.1% (v/v) Tween 20) for 1 h, and incubated with
primary antibodies at 4uC overnight prior to incubation for 1 h at
room temperature with the secondary antibody and, finally
development was carried out using an enhanced chemilumines-
cence (ECL) kit (Amersham Biosciences, Inc.). Bands obtained
were quantified by densitometry using Scion Image software. Pre-
and post-insulin protein lysates from each individual were run on
gels as pairs, with 4 volunteers per gel, along with a gel-to-gel
normalisation control (volunteer 14, BMI of 24). Densitometry
readings for every volunteer could then be normalised to volunteer
14 for comparison of either basal or post-insulin data. However
this normalisation was not required when assessing response to
insulin as this was done within a single immunoblot, after
normalisation to the appropriate loading control (phosphorylation
normalised to expression of same protein but on a separate gel
using same sample run at same time rather than following
stripping, while protein expression normalised to b-actin). To
ensure that individual biopsies contained an equal amount of
muscle protein and were not contaminated by variable amounts of
adipose tissue, the relative levels of Troponin C (muscle marker)
Skeletal Muscle Signalling Defects in Obesity
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and Fatty Acid binding protein-4 (adipose enriched protein also
called aP-2) were measured by immunoblot. The ratio of these
proteins did not vary by more than 20% across the entire 44
biopsies, and did not correlate with BMI or M-value (data not
shown).
Immunoprecipitation and kinase assays. Protein extracts
(50–250 mg) were incubated for 1 h on a shaking platform with
protein G-sepharose conjugated to 2 mcg of anti-PKB antibody
(PH domain), Upstate (Lake Placid, USA) or anti-p42/p44 MAP
kinase antibody from Abcam (Cambridge, UK). The immuno-
complexes were pelleted and washed with 1 ml of Lysis Buffer
containing 0.5 M NaCl, and twice with 1 ml of assay buffer
(25 mM MOPS pH 7.0, 0.4 mM EDTA, 0.1 M NaCl, 0.01%
Brij35 and 0.1% (v/v) 2-mercaptoethanol). The immunoprecipi-
tated kinases were incubated at 30uC for 30 min, in a total volume
of 50 mcl containing 25 mM MOPS (pH 7.0), 0.4 mM EDTA,
0.1 M NaCl, 0.01% Brij35, 0.1% (v/v) 2-mercaptoethanol,
10 mM MgCl, 0.1 mM [c-32P]ATP (0.56106 c.p.m./nmol) and
30 micromolar Crosstide (GRPRTSSFAEG) or 0.1 mM MBP as
respective substrates to PKB and ERK. A Unit of kinase activity is
defined as the amount which catalyses the phosphorylation of
1 nmol of substrate in 1 hour.
Insulin Sensitivity Calculations. Whole body insulin sen-
sitivity was assessed by determining the amount of glucose
metabolised (M value; mg.kg21.min21) according to the infusion
rate of exogenous glucose and using the space correction to
account for under or overfilling the glucose space, with blood
glucose concentrations recorded every five minutes during the final
20-minute period. Values are expressed per kilogram of total body
weight.
Antibodies. Rabbit polyclonal antibody to IRS1 (raised
against 14 C-terminal aminoacids) and a mouse monoclonal
PKB antibody (raised against the PH domain) were purchased
from Upstate Biotechnology (Lake Placid, NY, USA), the
antibodies to ERK1/2, FABP-4 and Troponin C were obtained
from Abcam (Cambridge, UK), and the antibody to b-actin was
purchased from Sigma-Aldrich (St Louis, MO, USA). Antibodies
against phospho-PKB (Ser473) and (T308), phospho-p42/p44
MAP kinase (Thr202/Tyr204), phospho-FOXO1 (Ser256), phos-
pho-GSK-3 a˜b (Ser9/21), GSK3-b and phospho-S6 ribosomal
protein (Ser240/244) were purchased from Cell Signalling
Technology (Danvers, MA, USA). The Division of Signal
Transduction and Therapy, University of Dundee generated the
antibodies to FOXO1 and p70S6 kinase in-house in sheep.
Statistical analysis
Correlation was performed using Pearson correlation for
normally distributed variables and using Spearman correlation
for variables not normally distributed.
Results
Biochemistry
Mean (6SD) fasting plasma glucose concentrations were all
within the normal concentration range at 5.160.6 mmol/l. Serum
insulin concentrations increased from a mean (6SD) fasting
concentration of 563 mU/ml (n= 11) to 62617 mU/ml after 1 h
of hyperinsulinaemia (n = 7).
Body composition
Of the 22 individuals, 7 were of normal weight (BMI, 20–
24 kg/m2), 5 were overweight (BMI 25–29 kg/m2) and 10 were
obese (BMI$30 kg/m2). 19 out of 22 individuals underwent body
composition analysis using whole body DEXA. There was a highly
significant correlation between BMI and fat mass, measured by
DEXA (r = 0.85; p,0.001).
Relationship between body composition and insulin
sensitivity
There was a highly significant inverse correlation between the
whole body insulin sensitivity, M value and BMI (r =20.85;
p,0.0001), lean body mass (r =20.8; p = 0.02) and percentage fat
mass (r =2.68; p = 0.01) (Figure 1), confirming that the lean
patients were insulin-sensitive and that there was an increasing
degree of IR relative to increasing obesity.
Figure 1. Relationship between whole body insulin sensitivity
and body mass index, lean body mass and percentage fat
mass.Whole body insulin sensitivity (M value; mg/kg/min) and A) body
mass index (kg/m2), B) lean body mass (kg) and C) percentage fat mass.
doi:10.1371/journal.pone.0056928.g001
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Protein expression
PKB and p42/44 MAPK. There was inter-individual vari-
ability in expression of PKB and p42/44 MAPK both in the fasted
or post 1 h insulin biopsies, with no correlation of each to either
BMI or whole body insulin sensitivity (M-value) (data not shown).
IRS1. Again, there was a great deal of inter-individual
variation in the IRS1 levels in the fasted state. IRS1 expression
in muscle increases following acute exposure to insulin (Figure 2, A
and B); there was no significant correlation between fold induction
of IRS1 protein expression in response to insulin and the BMI
(r =20.36; p = 0.10), or M value (r = 0.27; p = 0.23) (Figure 2, C
and D).
Phosphorylation status
PKB. The induction of PKB phosphorylation by insulin was
apparent in most volunteers (Figure 3 A and B). There was a
tendency for the degree of insulin-induced phosphorylation of
PKB to reduce with increasing BMI (r =2.38; p = 0.09) (C) and to
increase with increasing M value (r = 0.4; p= 0.08) (D) but these
failed to reach significance. In contrast to the analysis of p42/p44
MAPK, direct assay of PKB activity rather than western blotting
of phosphorylation failed to improve the correlation between PKB
activity and insulin sensitivity (data not shown).
p42/44 MAPK. There were no significant correlations
between basal p42/44 MAPK phosphorylation and either BMI
or M value (Figure 4). There was a tendency for p42/44 MAPK
phosphorylation following insulin exposure to correlate with BMI
(Spearman r= 0.4; p = 0.07) (C) or with M value (Spearman
r= 0.59; p = 0.08) (D) but these both failed to reach significance.
p42/44 MAPK Activity
It is widely appreciated that the western blot technique is semi-
quantitative (albeit technically relatively straightforward). There-
fore, since there was an indication that insulin regulation of p42/
44 MAPK phosphorylation may be reduced in the more insulin
resistant population, we decided to perform a more quantitative
analysis of p42/44 MAPK activation. p42 MAPK and p44 MAPK
were immunoprecipitated prior to an in vitro assay of activity, for
the pre- and post-insulin biopsies, for 17 of the 22 volunteers,
covering the full range of BMI and M-values. As with western blot
we found that there was a great deal of inter-individual variability
in the basal level of activity. There was no significant correlation
between either basal activity or post-insulin p42/p44 MAPK
activity levels, and M-value or BMI (Figure 5). However there was
an inverse correlation between fold-induction of p42/44 MAPK
activity by insulin and body mass index (r = 0.73; p = 0.0009)
(Figure 5A) and a significant correlation between p42/44 MAPK
activity in response to insulin and M value (r = 0.52; p= 0.04)
(Figure 5B). Thus, whether measured against the degree of obesity
or IR, the data indicates a close relationship between defective
response to insulin of p42/44 MAPK activity in muscle and the
clinical measures of pre-diabetes. This suggests that abnormal
p42/p44 MAPK response to insulin in skeletal muscle is a better
marker of whole body insulin resistance than the response of the
PI3K-PKB pathway, at least in obese non-diabetic individuals.
FOXO, GSK3 and ribosomal S6. There were no correla-
tions between the basal or insulin-induced levels of phosphoryla-
tion of FOXO, GSK3 and ribosomal S6 protein with either BMI
or M value (data not shown).
Figure 2. Relationship of IRS1 expression with body mass index or M value. Relative IRS1 protein expression according to body mass index
(A) or to M value (B) and fold increase in IRS1 expression according to body mass index (r =20.36; p = 0.10) (C) or to M value (r = 0.27; p = 0.23) (D).
doi:10.1371/journal.pone.0056928.g002
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Summary of signalling analysis (Table 1)
The study group was stratified incrementally according to their
whole body insulin resistance, determined by the M value, and the
responses of each individual signalling protein to insulin were
ranked and the four individuals with the greatest (Green numbers,
ranking 1 to 4)) or least (Red numbers, ranking 1 to 4) responses
for each protein were noted. Representative blots are shown
(Figure 6). The responses of interest were insulin-induced changes
in IRS1 protein expression, in PKB or p42/p44 MAP kinase
phosphorylation or in p42/p44 MAP kinase activity.
We observed a general clustering of the greatest signalling
responses to insulin within the more insulin sensitive individuals
(those with higher M values who tended to have lower BMIs) and
conversely the lowest signalling responses occur in the more insulin
resistant individuals (those with the lower M values who tended to
have higher BMIs). However, defects in multiple signalling
proteins often co-existed in the same individual but moreover no
single signalling defect explained insulin resistance in all obese
individuals.
Discussion
The main findings of the current study implicate, for the first
time, attenuation of insulin stimulation of the p42/p44 MAP
kinase pathway as an early defect in obesity-induced IR in skeletal
muscle. We observed an impaired insulin-induced stimulation of
skeletal muscle p42/p44 MAP kinase activity, in those individuals
with higher BMI or lower whole body insulin sensitivity (M value)
i.e. obese, IR individuals. Consistent with this finding, in the same
individuals, we observed blunting of insulin-induced phosphory-
lation of p42/p44 MAP kinase at the regulatory residues (Tyr185,
Thr183). Importantly, this signalling defect only became apparent
when assessing the magnitude of response to insulin, and was not
detectable by measuring p42/p44 MAP kinase activity or
phosphorylation, in the post-absorptive state, without insulin
stimulation. Our findings also suggest that multiple molecular
mechanisms may mediate skeletal muscle IR within different
overweight or obese individuals. Although defective p42/p44
MAP kinase signalling was the most prevalent in the volunteers
studied there was clear evidence of defects in other signalling
proteins including IRS1 and PKB in several individuals.
These observations are entirely consistent with previous
analyses from this group demonstrating an association of p42/
p44 MAP kinase signalling with stimulation of muscle glucose
transport [17] as well as a defective regulation of the p42/p44
MAP kinase pathway in different pathophysiological conditions
associated with skeletal muscle IR and reduced glucose transport.
First, in young women with PCOS, there was a severe attenuation
of insulin stimulation of the p42/p44 MAP kinase pathway in
muscle compared to controls (with p42/p44 MAP kinase activity
Figure 3. Relationship of PKB phosphorylation with body mass index or M value. Relative PKB phosphorylation according to body mass
index (A) or to M value (B) and fold increase in PKB phosphorylation by insulin according to body mass index (r =2.38; p = 0.09) (C) or to M value
(r = 0.4; p = 0.08) (D).
doi:10.1371/journal.pone.0056928.g003
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actually reducing in response to insulin) although the group was
too small to detect any correlation between BMI and the defective
regulation of p42/p44 MAP kinase in the PCOS group [2]. Others
have reported that the p42/p44 MAP kinase pathway is
constitutively activated both in vitro and in vivo in the skeletal
muscle of women with PCOS [18]. Similarly, in older healthy
subjects and in patients with T2DM, in whom skeletal muscle
uptake of 2-deoxyglucose was blunted compared with healthy
young men, reduced stimulation of p42/44 MAP kinase
phosphorylation was observed [14]. In contrast, Cusi et al reported
that insulin stimulation of the p42/p44 MAP kinase was normal in
obese and diabetic subjects [19]. Furthermore, Jager et al
demonstrated that specific inactivation of p44 MAP kinase in
obese, leptin deficient mice protected them against insulin
resistance despite massive obesity. These animals exhibited
relatively good whole-body insulin sensitivity and increased insulin
action in skeletal muscle compared to control animals [20].
However all of the studies suggest that this pathway exerts control
over insulin action, where chronic deletion may generate
compensatory insulin sensitising mechanisms but the initial loss
of insulin induction of p42/p44 MAP kinase may be a marker of
defective insulin action in muscle in response to obesity.
Others have suggested that defective IRS1 or IRS2 signalling is
present in muscle of patients with T2DM. Supporting this
hypothesis, a genetic variant near IRS1, that is associated with
reduced basal levels of IRS1 protein and decreased insulin
induction of IRS1-associated PI-3K activity in human skeletal
muscle biopsies, is associated with type 2 diabetes, insulin
Figure 4. Relationship of ERK phosphorylation with body mass index or M value. Relative ERK phosphorylation according to body mass
index (A) or to M value (B) and fold increase in ERK phosphorylation by insulin according to body mass index (r = 0.4; p = 0.07) (C) or to M value
(r = 0.59; p = 0.08) (D).
doi:10.1371/journal.pone.0056928.g004
Figure 5. Fold activation of ERK by insulin according to body
mass index or M value. (A) Body mass index (r = 0.73; p = 0.0009) or
(B) M value (r = 0.52; p = 0.04).
doi:10.1371/journal.pone.0056928.g005
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resistance and hyperinsulinemia [21]. We have previously
reported a significant increase in IRS1 protein expression
following acute insulin treatment of human muscle [11]; however
the fold induction of IRS1 expression in response to insulin in this
study was not correlated with either BMI or M value. We cannot
rule out abnormalities in one or more of the many post
translational modifications of this protein (or its homologue
IRS2), however we have focussed on distal signalling mechanisms
where deficits in IRS1 function would still be detectable. For
example, a mutation in PKB beta has been found to associate with
severe IR and lipodystrophy, demonstrating the importance of the
IRS-PI3K-PKB pathway to insulin sensitivity [22], although
mutations in this protein appear to contribute to only a very
small fraction of IR in the population [23]. Our data suggest that
there are relatively few cases of defective IRS1-PKB signalling that
correlate with obesity induced insulin resistance in an otherwise
healthy population. We measured protein expression, the phos-
phorylation (at a residue known to regulate activity in response to
insulin) and where possible the inherent activity of PKB, p42/p44
MAPK GSK3, FOXO1 and p70S6K. Although we could not
detect abnormalities in PKB activation by insulin, there was an
indication that the phosphorylation of PKB at Ser473 may be
higher in the muscle of the more insulin sensitive group, at least
after exposure to insulin, although the differences were not
significant. Indeed, the dissociation of whole body IR from defects
in proximal insulin signaling in obese volunteers that we observe
are also consistent with those observations of several other groups
[24,25]. GSK3 and FOXO are more distal downstream targets of
PKB while S6 protein is regulated by the mTOR pathway [26].
No significant differences were observed in basal or insulin-
induced phosphorylation of these molecules. This provides added
confidence that the PI-3K pathway is responding to insulin in a
similar fashion across the population studied.
Despite the correlation of defective p42/p44 MAP kinase
activation and poor insulin sensitivity there were still some obese,
insulin resistant individuals in whom p42/p44 MAP kinase could
readily be activated in response to insulin (Fig.4). However, in all
of the most insulin resistant subjects at least one major signalling
defect in their muscle was evident, when assessed as response to
insulin (but not when examined as activity or expression of a signalling
molecule in the post-absorptive state). However, the individuals with the
greatest induction of these molecules tended to have lower BMI
and higher M-values, and conversely the subjects with poorest
responses to insulin at the molecular level generally also had low
M-values and high BMI scores (Table 1). It is worth noting that
the 10 individuals with lowest whole body insulin sensitivity had
complete loss of insulin induction of at least one of the major
signalling molecules. However it was not always the same
molecular defect: for example in subjects 15, 5 and 8, p42/p44
MAP kinase activity was suppressed (instead of increased) in
response to insulin, while subject 22 exhibited no insulin induction
of PKB phosphorylation or IRS1 protein (despite strong induction
of p42/p44 MAPK phosphorylation and activity). It is not
immediately obvious why different signalling defects should arise
in a relatively healthy obese population, however it may be related
to dietary variations with different compositions of fatty acids
altering signalling in different ways [27], or other lifestyle factors
not apparent in our study. This aspect, as well as establishing
Table 1. Summary table.
BMI M-value
IRS1 protein
expression
Change in PKB
phosphorylation
p42/44 MAP kinase
phosphorylation
p42/44 MAP kinase
activity
36 0.9 L2 L4
35 1.8 L1 L3 H2
35 2.5
37 3.2 L4 L1 L2 L1
27 3.7 L4 H1
33 3.9 H1
31 4.3 L3 L2
30 4.5 H3 H3 L1 L2
30 5 L4
31 5 L3 L3
24 5.4 H4
29 5.9
24 6 H1
28 6 H4
29 6.4
28 7.6 H2 H3 H2
20 7.6 H4
24 8.7
22 9.1 H2 H1
22 9.4
22 11.5 H4 H3
The study group is presented from the lower to the higher M-value, demonstrating clustering of signalling abnormalities stratified in ascending order according to the
induction of signalling changes in response to insulin. Least potent induction is ranked as lowest L1 to L4; most potent induction is ranked as highest H1 to H4.
doi:10.1371/journal.pone.0056928.t001
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whether one signalling defect is more liable to promote diabetes,
deserves further investigation.
In summary, aberrant p42/p44 MAPK signalling was the most
common problem found in obesity-induced insulin resistant
skeletal muscle. However, multiple defects in insulin signal
transduction were apparent in this group and it will be of interest
to establish whether the p42/p44 MAPK defect is associated with
progression to T2DM.
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